ArticleAmerican journal of cancer research2025
Characterization of TrkB autoantibodies reveals an agonist binding region in breast cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neurotrophin receptor TrkB has been increasingly implicated in the progression, metastasis, and drug resistance of breast cancer. While its natural ligand, brain-derived neurotrophic factor (BDNF), activates TrkB signaling to promote tumor cell proliferation and survival. In this study, we identified that certain patient-derived antibodies can function similarly as agonists, we investigated their binding region and functional activities using a reporter cell assay and a combination of epitope mapping. Our results reveal distinct binding patterns associated with agonistic activity and identify a key activation site targeted by these antibodies. These findings suggest that TrkB agonist autoantibody mediated modulation of this region may influence cancer cell signaling and providing a potential basis for further investigation into immune-related mechanisms in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.